Skip to content
    Clinical Trials

    Study shows reprogramming thyroid tumors may improve CAR-T cell therapy

    Ferris-TillmanMayo Clinic

    Study shows reprogramming thyroid tumors may improve CAR-T cell therapy
    In a preclinical study published in Molecular Cancer, Mayo Clinic researchers demonstrated that pharmacologic tumor redifferentiation can overcome antigen loss, a key mechanism of immune evasion in solid tumors. While chimeric antigen receptor (CAR)-T cells engineered against the thyroid-stimulating hormone receptor (TSHR) display potent activity against thyroid cancers with high baseline target expression, their efficacy is severely restricted in anaplastic thyroid cancer due to absent or minimal TSHR surface levels.
    To address this challenge, investigators utilized mitogen-activated protein kinase (MAPK) pathway inhibitors, specifically trametinib and dabrafenib—agents currently approved for advanced thyroid cancer—to induce redifferentiation in patient-derived anaplastic thyroid cancer models. MAPK inhibition successfully upregulated TSHR expression on aggressive tumor cells, rendering previously undetected cancer cells visible to engineered TSHR-targeted CAR-T cells.
    Importantly, the MAPK inhibitors did not diminish CAR-T cell viability, expansion, or cytotoxic capabilities. Although target receptor density subsided upon drug withdrawal, a two-week concurrent treatment window was sufficient to achieve superior antitumor activity and survival outcomes compared to either single-agent approach. Investigators are now completing preparatory translational studies to support a phase 1 clinical trial evaluating TSHR-targeted CAR-T cell therapy as a monotherapy for TSHR-retaining disease and in combination with MAPK inhibitors for antigen-deficient tumors.

    Key Takeaways

    • In preclinical patient-derived models of anaplastic thyroid cancer, combining MAPK pathway inhibitors (trametinib and dabrafenib) with TSHR-targeted CAR-T cells resulted in superior tumor control and survival compared to either modality alone.
    • Two weeks of concurrent MAPK inhibition restored thyroid-stimulating hormone receptor expression on aggressive tumor cells to enhance CAR-T activity without compromising T-cell proliferation or cytolytic function.